Omadacycline

Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass[2] of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections. Contents 1 In vitro studies 2 Mechanism of action 3 Clinical trials 4 Discovery 5 References 6 External links In vitro studies In vitro studies h... [wikipedia]